Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adderex XR is an over-the-counter nootropic dietary supplement developed by Hi-Tech Pharmaceuticals. It is marketed as a cognitive enhancer designed to support increased concentration, focus, motivation, productivity, and mood. The product utilizes a proprietary blend of several phenylethylamine (PEA) and methylphenylethylamine alkaloids—compounds structurally related to amphetamines but available without prescription. These ingredients act as central nervous system stimulants by promoting the release of neurotransmitters such as dopamine and norepinephrine in the brain, which are associated with improved attention, alertness, and well-being. The formulation features both rapid-release and extended-release technologies for sustained effects throughout the day[2][6][10]. Adderex XR does not contain prescription amphetamines or dextroamphetamine salts found in drugs like Adderall XR; instead, it relies on PEA derivatives sourced from Senegalia berlandieri and other sources[10]. It is positioned as an alternative for individuals seeking focus aids without a prescription.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Adderex XR.